Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024


Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results and provide full-year 2024 guidance.

To pre-register for the conference call please use this link:

Registration Link: https://www.netroadshow.com/events/login?show=71651ed6&confId=60623. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Wednesday, March 20, 2024, at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code 671547. In addition, a live audio of the conference call will be available as a webcast. To join the webcast, please visit "Events" on investor relations page of the Company's website at www.xerispharma.com.

About Xeris Biopharma Holdings, Inc.

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing's syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSoltm and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn or Instagram.


These press releases may also interest you

at 12:00
OBiO Technology will showcase at American Society of Gene & Cell Therapy
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...

at 12:00
SightMD Pennsylvania Expands Practice with Acquisition of James Lewis, MD
SightMD Pennsylvania, a leading multi-specialty ophthalmology platform, is pleased to announce the acquisition of James Lewis, MD. Through this strategic partnership, Dr. Lewis's practice at 8380 Old York Rd Ste 110, Elkins Park, PA 19027 will expand...

at 11:56
OCSTA Responds to Provincial Policy Announcement on the Use of Cellphones and Vaping in Schools
" Catholic school boards and their dedicated staff work tirelessly in support of the mental, physical, intellectual, and spiritual well-being of students in Catholic schools," said Patrick Daly, President of the Ontario Catholic School Trustees'...

at 11:30
Violence doesn't stop at the walls.
On April 28 of every year, Canada observes its National Day of Mourning in commemoration of those who have lost their lives, suffered illness or injury on the job or experienced a work?related tragedy. This year, the Union of Canadian Correctional...

at 10:59
Juewei brand meat and vegetable products recalled due to Listeria monocytogenes
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution: AlbertaBritish ColumbiaPossibly other provinces and territories See the affected products and product photos for this recall SOURCE Canadian Food...

at 09:53
Kingwuu brand and T&T Kitchen brand meat and vegetable products recalled due to Listeria monocytogenes
Product: Meat and vegetable products Issue: Food ? Microbial Contamination ? Listeria Distribution:AlbertaBritish ColumbiaPossibly other provinces and territories See the affected products and product photos for this recall   SOURCE Canadian Food...

More news about Health...


News published on and distributed by: